Literature DB >> 17673379

Matriptase expression in the normal and neoplastic mast cells.

Ming-Fang Cheng1, Jong-Shiaw Jin, Huang-Wei Wu, Pei-Chun Chiang, Lai-Fa Sheu, Herng-Sheng Lee.   

Abstract

Matriptase, a type II transmembrane serine protease, is distributed in almost all normal human epithelium. Several studies have demonstrated that matriptase expression is correlated with tumor progression in epithelium-derived cancer cells. Mast cells, which originate from pluripotent hematopoietic cells in the bone marrow, can produce and store almost cellular-specific neutral serine proteases, such as tryptase and chymase, and are functionally involved in both the immediate hypersensitivity response and anaphylactic shock. Mast cells are significantly increased in several neoplasms, indicating that they most likely play a role in degrading the tissue matrix. Recently, trypsin has been revealed to activate the latent matriptase on the surface of several human cancer cell lines, suggesting that matriptase and trypsin cooperatively function in extracellular proteolysis. In our study, almost all mast cells in tissues throughout the body stained positive for matripase. Matripase was also found in neoplastic mast cells. To our knowledge, this is the first time that matriptase has been shown to be expressed by mast cells. Therefore, we suggest that this expression of matriptase may not only be useful as an additional marker for mast cells but also be involved in their physiopathological function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673379     DOI: 10.1684/ejd.2007.0233

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  10 in total

1.  Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade.

Authors:  Zhenghong Xu; Ya-Wen Chen; Aruna Battu; Paul Wilder; David Weber; Wenbo Yu; Alexander D Mackerell; Li-Mei Chen; Karl X Chai; Michael D Johnson; Chen-Yong Lin
Journal:  J Med Chem       Date:  2011-10-12       Impact factor: 7.446

2.  Matriptase is inhibited by extravascular antithrombin in epithelial cells but not in most carcinoma cells.

Authors:  Feng-Pai Chou; Han Xu; Ming-Shyue Lee; Ya-Wen Chen; O X Durand Richards; Richard Swanson; Steven T Olson; Michael D Johnson; Chen-Yong Lin
Journal:  Am J Physiol Cell Physiol       Date:  2011-07-27       Impact factor: 4.249

3.  Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1.

Authors:  Baoyu Zhao; Cai Yuan; Rui Li; Dan Qu; Mingdong Huang; Jacky Chi Ki Ngo
Journal:  J Biol Chem       Date:  2013-02-26       Impact factor: 5.157

4.  A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation.

Authors:  Stine Friis; Katiuchia Uzzun Sales; Sine Godiksen; Diane E Peters; Chen-Yong Lin; Lotte K Vogel; Thomas H Bugge
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

Review 5.  Membrane-anchored serine proteases in health and disease.

Authors:  Toni M Antalis; Thomas H Bugge; Qingyu Wu
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

6.  Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.

Authors:  Katiuchia Uzzun Sales; Andrius Masedunskas; Alexandra L Bey; Amber L Rasmussen; Roberto Weigert; Karin List; Roman Szabo; Paul A Overbeek; Thomas H Bugge
Journal:  Nat Genet       Date:  2010-07-25       Impact factor: 38.330

7.  Structure of catalytic domain of Matriptase in complex with Sunflower trypsin inhibitor-1.

Authors:  Cai Yuan; Liqing Chen; Edward J Meehan; Norelle Daly; David J Craik; Mingdong Huang; Jacky C Ngo
Journal:  BMC Struct Biol       Date:  2011-06-22

8.  Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells.

Authors:  Pengming Sun; Lifang Xue; Yiyi Song; Xiaodan Mao; Lili Chen; Binhua Dong; Elena Loana Braicu; Jalid Sehouli
Journal:  Oncotarget       Date:  2018-01-03

9.  Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1.

Authors:  Bernhard Glotzbach; Michael Reinwarth; Niklas Weber; Sebastian Fabritz; Michael Tomaszowski; Heiko Fittler; Andreas Christmann; Olga Avrutina; Harald Kolmar
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

10.  Human cancer cells retain modest levels of enzymatically active matriptase only in extracellular milieu following induction of zymogen activation.

Authors:  Li-Ling Chu; Yuan Xu; Jie-Ru Yang; Yi-An Hu; Hsiang-Hua Chang; Hong-Yu Lai; Chun-Che Tseng; Hue-Yu Wang; Michael D Johnson; Jehng-Kang Wang; Chen-Yong Lin
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.